<DOC>
	<DOCNO>NCT00048204</DOCNO>
	<brief_summary>A Placebo Controlled Study Evaluating Efficacy And Safety Medication In Patients With Major Depressive Disorder ( MDD )</brief_summary>
	<brief_title>A Study Of A New Medicine ( GW597599B ) For The Treatment Of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>Patients meet diagnosis Major Depressive Disorder ( MDD ) . Patients primary diagnosis MDD . Patients history schizophrenia , schizoaffective disorder , seizure disorder bipolar affective disorder . Patients receive formal psychotherapy cognitive/behavioral therapy concurrently 12 week prior screen visit . Patient actively suicidal . Patients history migraine headache .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Psychiatry</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>